About Abraham Van Wyk
Abraham Van Wyk is a cofounder and director at Metanoia Bio.
Form D filings also name Abraham Van Wyk as a director at GRI Bio.
Abraham Van Wyk first appears on SEC filings in 2015.
Experience
This experience comes from Abraham Van Wyk's profile and from SEC filings. For roles taken from filings, the years are when the filings name Abraham Van Wyk in the role, so the role may have started earlier or lasted longer.
Metanoia Bio Inc Current
Cofounder and director
Co-Founder and President (2020 – Present)
2020 – Present · Lewes, DE
Develops potential treatments for people with type 2 diabetes.
TG
Troy Gold Current
Director
2018 – Present
BI
Bugworks Research Inc. Current
Investor and Board Observer
2017 – Present
NI
nuvoteQ.io Current
Co-Founder and Board Member
2015 – Present
AC
Acquipharma Current
General Partner
2014 – Present
BI
Burl Concepts, Inc. Current
Investor and Board Observer
2014 – Present
FI
FHI Clinical Inc.
Chief Financial Officer
2022 – 2026
Gri Bio Operations, Inc.
Director
2014 – 2023 · LA Jolla, CA
Develops potential treatments for people with inflammatory, fibrotic and autoimmune diseases.
TR
TCD Outcomes Research
Board Member
2015 – 2022
TD
Triclinium Clinical Development
CEO
2015 – 2022
CL
Cytespace Research Private Limited
Board Member
2012 – 2022
CS
Clinical Information Solutions
Co-Founder
2012 – 2014
QU
Quintiles
Associate Director, Region Head
2007 – 2012
MM
Medical University of South Africa, Medunsa
Lecturer
2006 – 2007
Key Colleagues at Startups
The people Abraham Van Wyk works with at each company, as listed on that company's latest Form D.
Metanoia Bio Inc · Form D, Mar 18, 2026
ST
Slavica Tudzarova
Scientific Cofounder
HM
Hilton Mendelsohn
Cofounder
BC
Brent Cohen
Chairman
OG
Oppel Greeff
Cofounder and director
Gri Bio Operations, Inc. · Form D, Apr 17, 2015
RW
Raymond Watt
Director
WH
Walter Hertz
President and CEO, director
AA
Albert Agro
Director
OG
Oppel Greef
Executive officer
VC
Vipin Chaturvedi
Executive officer and director